These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation]. Huang XJ; Liu DH; Xu LP; Han W; Jiang Q; Chen YH; Zhang YC; Liu KY; Bao L; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):548-50. PubMed ID: 16468333 [TBL] [Abstract][Full Text] [Related]
6. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350 [TBL] [Abstract][Full Text] [Related]
7. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb immunoadsorption. Rabitsch W; Knöbl P; Prinz E; Keil F; Greinix H; Kalhs P; Worel N; Jansen M; Hörl WH; Derfler K Bone Marrow Transplant; 2003 Nov; 32(10):1015-9. PubMed ID: 14595389 [TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation. Fang B; Song Y; Li N; Li J; Han Q; Zhao RC Ann Hematol; 2009 Mar; 88(3):261-6. PubMed ID: 18769919 [TBL] [Abstract][Full Text] [Related]
10. ABO incompatible stem cell transplantation in children does not influence outcome. Helming AM; Brand A; Wolterbeek R; van Tol MJ; Egeler RM; Ball LM Pediatr Blood Cancer; 2007 Sep; 49(3):313-7. PubMed ID: 16960869 [TBL] [Abstract][Full Text] [Related]
11. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components. Rowley SD; Liang PS; Ulz L Bone Marrow Transplant; 2000 Oct; 26(7):749-57. PubMed ID: 11042656 [TBL] [Abstract][Full Text] [Related]
12. [Pure red cell aplasia after allogeneic transplantation of ABO incompatible hematopoietic stem cells]. Bullorsky E; Shanley C; Stemmelin G; Ceresetto J; Rabinovich O Medicina (B Aires); 2002; 62(6):575-7. PubMed ID: 12532694 [TBL] [Abstract][Full Text] [Related]
13. What is the optimal approach to major ABO-incompatible allogeneic stem cell transplantation? Sheppard D; Huebsch LB; Bredeson C Biol Blood Marrow Transplant; 2013 Dec; 19(12):1760. PubMed ID: 24120381 [No Abstract] [Full Text] [Related]
14. Response to "What is the optimal approach to major ABO-incompatible allogeneic stem cell transplantation". Booth GS; Gehrie EA; Savani BN Biol Blood Marrow Transplant; 2013 Dec; 19(12):1760-1. PubMed ID: 24125949 [No Abstract] [Full Text] [Related]
15. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation. Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic bone marrow transplantation from a major ABO-incompatible donor. Infusion of hemopoietic stem cells isolated by Ficoll-Hypaque method. Harada M; Aoyagi N; Kondo K; Ishino C; Odaka K; Matsue K; Yoshida T; Hattori K Transplantation; 1983 Feb; 35(2):191-2. PubMed ID: 6131551 [No Abstract] [Full Text] [Related]
17. Detection of IgG anti-A/B must be essential for safe transfusion support in patients undergoing ABO incompatible allogeneic HSCT. Liu F; Li G; Mao X; Hu L Transfus Apher Sci; 2011 Apr; 44(2):123-7. PubMed ID: 21320800 [TBL] [Abstract][Full Text] [Related]